Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du

Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du

Item

http://www.wikidata.org/entity/Q33416427

Q33416427

about

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond New criteria for response assessment: role of minimal residual disease in multiple myeloma Recent advances in understanding multiple myeloma Optimal maintenance and consolidation therapy for multiple myeloma in actual clinical practice Flow cytometry quality requirements for monitoring of minimal disease in plasma cell myeloma.Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist.Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple Myeloma Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operativ High expression of endoplasmic reticulum chaperone grp94 is a novel molecular hallmark of malignant plasma cells in multiple myeloma Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party.Multiple myeloma in the marrow: pathogenesis and treatments.Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma.The role of pre-transplant induction regimens and autologous stem cell transplantation in the era of novel targeted agents.Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study.Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma.Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand?Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.An update on the use of lenalidomide for the treatment of multiple myeloma.Clinical treatment of newly diagnosed multiple myeloma.Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT.Oral ixazomib maintenance therapy in multiple myeloma.Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.The role of tandem stem cell transplantation for multiple myeloma patients.Impact of lenalidomide-based induction therapy on the mobilization of CD34(+) cells, blood graft cellular composition, and post-transplant recovery in myeloma patients: a prospective multicenter study.Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma.Consolidation and Maintenance Therapies for Newly Diagnosed Multiple Myeloma in the Era of Novel Agents.A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma.Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials Management of high-risk Myeloma: an evidence-based review of treatment strategies.Multiple myeloma: disease response assessment.Multiple Myeloma Minimal Residual Disease.Lenalidomide, Bortezomib, and Dexamethasone (RVD) Regimen for Multiple Myeloma.High-risk multiple myeloma: a multifaceted entity, multiple therapeutic challenges.Concomitant MDS with isolated 5q deletion and MGUS: case report and review of molecular aspects.IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM).VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma.Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.

P2860

Q26766718-707920CE-CBC7-4CFA-9853-9B7F2C36EF93 Q27027512-0974BB5D-961F-4FAD-9B6E-28FACAD48162 Q28070331-8253621F-7F84-45D9-9F83-9EC39BCB6F5A Q28077567-17E675C3-D6FA-4A05-83DD-F7826D39A6A2 Q33602593-E390D6CA-19CB-456A-AD97-2DD3DE3A6443 Q34551324-BADC1BA8-1AA0-433A-86F7-24FFFB707844 Q34694749-EE2E9EA7-56A4-490F-8DDD-7C7AA5A5DE54 Q35571048-F8924790-B99C-4D67-AD2D-211A85B76784 Q35789280-E87BB9EE-5ABB-4491-BFD6-0DB97E49B008 Q35800851-77AD0C9C-E076-4604-99C3-A47F866B0E4C Q36000415-819F23BD-4289-4B83-80CD-9244A1785EF0 Q36725401-7211397B-0CE2-4437-B47A-A0A3F26E6261 Q36963203-8A53B40D-5A12-4879-9130-1CF486F08E5F Q37037265-A716D422-C64A-482B-B5A7-4BECE9594CC2 Q37373159-36FF8E98-BC87-4ECE-A936-97939AD10181 Q38375463-61C937E3-E29F-4282-B74B-D9ED5A2B628E Q38385471-BB58ADE9-6F75-4F71-9D25-7EB7CEC968BF Q38413040-214EC6FA-5FFC-47DF-BD85-8FD59DA54EF3 Q38429817-61683DE5-6439-47E0-BB64-AE563F2555FA Q38534837-A20FC4D0-622D-41F5-A7BE-64EBD0D327F5 Q38545607-D2D10DDD-382F-495C-8A79-0A081A5AE6D6 Q38578071-0D5EB5D0-A574-41AB-93F3-D2F1A3CA978F Q38632778-0FF37DFA-EA0F-4FE3-BDC9-466AB3732C36 Q38640514-ADF631F7-61F4-45B2-BE49-DC47974003A8 Q38650700-7A34FD8F-1AE4-4251-9D78-DAFB57816709 Q38677358-D6FF97EC-B4FD-4DE7-BD32-68D51CE9CBC6 Q38691698-C85598B9-ECCF-4F07-9097-172B9D2F9975 Q38738098-FBAE80CF-FC37-42DF-9E51-3248DA484BF0 Q38740213-47B07CA2-A0D2-48AD-99AB-7E44F5A38367 Q38771752-895726D8-2AD5-46A0-879C-E16BEB09944E Q38789282-339079A4-2B3C-48A3-848C-6D4309FE19B3 Q38874675-D375D15D-4908-43BE-81FE-3073373C86A5 Q38895092-D4B1A2B5-F31C-4A05-98FE-3C40712B32AC Q38970590-A0AC3F2F-C6EE-4A7D-A682-0CA96F02BAF3 Q38970962-1ACC102A-8FB4-4252-B774-A537CA467732 Q38979403-78426313-7228-4565-8854-57C9F51719A3 Q39013004-6085590F-4090-4A01-AA2C-9586BB0632E0 Q39065368-73E04DEE-84D4-4851-BE36-7786E1754F16 Q39103567-114FD964-BD0D-4171-89EF-C875C4DD3B66 Q39386287-C313DBBF-4CD9-4DF5-971B-8344D45167E0

P2860

Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du

Item

http://www.wikidata.org/entity/Q33416427

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue